In all participants, anti-S IgG avidity significantly increased with each successive dose of vaccine, plateauing after 3 vaccine doses in anti-IL-12/23–treated and anti-TNF–treated patients with IBD (Figure 7A and Supplemental Table 4). This evidence concerns the gene TNF and inflammatory bowel disease.